Nautilus Biotechnology, Inc. (NAUT) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.97

From 52W high−75.54%

Volume1.77M

Market cap$122.93M

P/E (TTM)—

P/S (TTM)647.0x

Div yield—

Key dataSep 18, 2026

Open

$0.97

From 52W high

−75.54%

Volume

1.77M

Market cap

$122.93M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.2x

P/E (TTM)

—

RSI (14)

45.6

MomentumView details →

1D Return

−0.59%

YTD Return

−51.78%

SummaryUpdated Jun 1, 2026

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) is a development-stage life sciences company founded in 2016 and headquartered in Seattle, Washington. The company went public in August 2020 and is focused on developing revolutionary proteomics technology to unlock the complexity of the human proteome - the complete set of proteins produced by an organism. Nautilus is creating a platform that promises to dramatically advance protein analysis capabilities, potentially transforming how researchers study diseases, develop drugs, and understand biological processes at the molecular level.

Ask drillr about Nautilus Biotechnology, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.2x

EV/Sales

351.1x

P/S (TTM)

647.0x

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

−919.47%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−43.11%

ROA (TTM)

−34.55%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+13.46%

FCF YoY

+7.86%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+16.07%

EBITDA YoY

+2.63%

MomentumView details →

1D Return

−0.59%

YTD Return

−51.78%

1Y Return

+38.08%

RSI (14)

45.6

vs 50D SMA

−16.85%

vs 200D SMA

−55.44%

Capital & dividendView details →

Debt/Equity

0.21x

Current Ratio

10.14x

Quick Ratio

10.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.11

EPS Surprise

18.52%

Beats (12Q)

12/12

Next Q EPS Est

−$0.14

Avg Surprise (4Q)

17.71%

Rev Surprise

90.00%

Financials snapshotView financials →

Revenue (TTM)

190000.00

Net Income (TTM)

−56.52M

Op. CF (TTM)

−50.23M

Next earningsOct 27, 2026 →

Latest newsMore news →

Nautilus Biotechnology, Inc. mutually terminated its prior at-the-market equity offering program with TD Securities (USA), LLC as sales agent.9d ago

Nautilus Biotechnology, Inc. entered into a sales agreement to sell up to $125,000,000 of common stock through an at-the-market offering program, with TD Securities (USA), LLC acting as sales agent.9d ago

Similar companies

Equillium, Inc.EQ Cibus, Inc.CBUS ProMIS Neurosciences, Inc.PMN vTv Therapeutics Inc.VTVT OnKure Therapeutics, Inc.OKUR LENZ Therapeutics, Inc.LENZ Find similar companies →

Latest newsMore news →

Nautilus Biotechnology, Inc. mutually terminated its prior at-the-market equity offering program with TD Securities (USA), LLC as sales agent.9d ago Nautilus Biotechnology, Inc. entered into a sales agreement to sell up to $125,000,000 of common stock through an at-the-market offering program, with TD Securities (USA), LLC acting as sales agent.9d ago Nautilus Biotechnology reported Q2 2026 financial results with total revenue of $0.2 million and a net loss of $14.5 million.55d ago